Overcoming the hurdles
presented by inherited retinal disease

ATSENA THERAPEUTICS’ programs include cutting-edge gene therapies for X-linked retinoschisis (XLRS), Leber congenital amaurosis 1 (LCA1), and MYO7A-associated Usher syndrome (USH1B). Our pipeline of proprietary assets is powered by adeno-associated virus (AAV) technologies engineered to overcome the unique hurdles presented by inherited retinal disease.